T-DM1 was tested in the phase 3 Katherine trial, involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.